FDA begins sharing rejection letters drugmakers often kept secret
Investors have long asked the FDA to share its reasons for rejecting drugs, arguing that companies can use the agency’s silence on the matter to mislead the market.
Pharmaceutical
Articles
Prices for obesity drugs fall, but affordability still out of reach for many
The medications still amount to around $500 per month for those without insurance—out of reach for many patients. And even for people with insurance, coverage remains uneven.
Lilly drug saves muscle when added to Wegovy weight-loss shot
The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.
Purdue Pharma’s $7B opioid settlement plan in judge’s hands
Most of the money would go to state and local governments to address the nation’s addiction and overdose crisis, but potentially more than $850 million would go directly to individual victims.
FDA to offer faster drug reviews to companies promoting ‘national priorities’
Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months.
Pharmaceutical company planning to relocate from California to Fishers
1Elevan Biopharmaceuticals plans to relocate to a vacant industrial building near Interstate 69 and East 121st Street, where it expects to build a workforce of at least 120 employees over the next decade.
Indiana to receive up to $100M as part of $7.4B opioid settlement
Indiana Attorney General Todd Rokita said the agreement addresses the devastating impact of Purdue Pharma’s aggressive marketing of opioid products under the Sackler family’s ownership, which “fueled the worst drug crisis in U.S. history.”
Lilly says weight loss pill has vast opportunity
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other conditions because it comes in pill form, not an injection.
Lilly, Purdue Strategic Ventures invest in AI-assisted remote lab platform built for speedier research and development
Persist AI announced a $12 million Series A funding round to support its new Cloud Lab platform, allowing companies to use its lab remotely for research and development.
Reports: Lilly eyes Houston for new $5.9B manufacturing facility
Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.
Lilly seeks to expand pain pipeline with $1B acquisition
SiteOne Therapeutics is developing a non-opioid therapy that targets sodium ion channels in the human body to treat pain and sensory hyperexcitability disorders.
Weight-loss drugs may lower cancer risk in people with diabetes, study suggests
The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting.
CEO of Novo Nordisk, maker of weight loss drug Wegovy, to step down
The Danish pharmaceutical company, which competes heavily with Indianapolis-based Eli Lilly and Co. in the weight-loss market, is leaving by “mutual agreement” with the company’s board of directors.
Overdose deaths in United States fell last year in largest one-year decline on record
Experts say more research needs to be done to understand what drove the reduction, but they mention several possible factors.
Trump signs order setting 30-day deadline for drugmakers to lower prescription drug costs
The sweeping executive order sets a deadline for drugmakers to lower the cost of prescription drugs in the United States or face new limits over what the government will pay.
Lilly’s Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the medications.
Trump promises to order that United States pay same price other nations do for some drugs
The proposal, expected to be announced by President Trump on Monday, will face fierce opposition from the pharmaceutical industry.
Trump drug price idea could cost industry $1 trillion, lobbying group says
The idea, floated by the White House as a way to help pay for the president’s tax cut plan, blindsided the pharmaceutical industry and has prompted a furious lobbying campaign.
Lilly shares plunge after CVS Health drops Zepbound from preferred coverage
CVS Health’s pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.
Walgreens to pay up to $350M in opioid settlement
The U.S. Department of Justice accused the pharmacy of illegally filling millions of prescriptions in the last decade for opioids and other controlled substances.